disruptpress efi

Johnson & Johnson reports $100 million in quarterly sales from Covid vaccine

In this article

A Johnson & Johnson building is shown in Irvine, California.
Mike Blake | Reuters

Johnson & Johnson on Tuesday reported $100 million in first-quarter sales of its Covid-19 vaccine that’s on hold in the U.S. while U.S. health regulators investigate a rare blood-clotting issue.

In releasinging its first-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.

Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: $2.59 per share versus $2.34 expected.
  • Revenue: $22.32 billion versus $21.98 billion expected.

J&J’s financial results come as the company’s Covid-19 vaccine has been put on pause in the United States after six women developed a rare but potentially life-threatening blood clotting disorder that left one dead and one in critical condition.

This is a developing story. Please check back for updates.

Products You May Like

Articles You May Like

Days Ahead Of First Federal Stimulus Payments, Local Governments Still Don’t Know How—And In Some Cases If—They’ll Spend The Money
Still missing a stimulus check? What to know about claiming the funds
Paycheck Protection Program has run out of money for most borrowers. What you need to know
From Lumber To TIPS To Bitcoin: 12 Inflation-Hedging Investment Moves
Another Eight-Figure Pocket Deal: Patriots Owner Robert Kraft Snags $43 Million Hamptons Mansion

Leave a Reply

Your email address will not be published. Required fields are marked *